Kymera Therapeutics, Inc.
NASDAQ:KYMRBiotechnology
Healthcare
$119.39 +1.67%
+$1.50 today
- Market cap
- $10.19B
- Beta
- 2.03
- P/E (TTM)
- -28.3
- EPS (TTM)
- -$3.23
52W Low $36.65High $103.00
Volume 0.72M
Average 0.58M
Income Statement
Follow revenue through to earnings.
Revenue
$39.20M
FY 2025 · Annual
-16.7% YoYOperating Income
-$349.40M
FY 2025 · Annual
Net Income
-$311.40M
FY 2025 · Annual
Income Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 72.83M | 46.83M | 78.59M | 47.07M | 39.2M |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 72.83M | 46.83M | 78.59M | 47.07M | 39.2M |
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Research & Development | 137.02M | 164.25M | 189.08M | 240.25M | 316.6M |
| Selling, General & Admin | 36.35M | 43.83M | 55.04M | 63.53M | 68.2M |
| Operating Expenses | 173.36M | 208.08M | 244.12M | 308.71M | 388.6M |
| Depreciation & Amortization | 2.4M | 2.98M | 3.57M | 7.37M | 8.31M |
| EBITDA | (97.65M) | (151.66M) | (143.2M) | (216.24M) | (303.06M) |
| EBITDA Margin | -134.1% | -323.9% | -182.2% | -459.4% | -773.1% |
| Operating Income | (100.53M) | (161.26M) | (165.53M) | (261.64M) | (349.4M) |
| Operating Margin | -138.0% | -344.4% | -210.6% | -555.8% | -891.3% |
| Interest Income | 488K | 6.62M | 18.76M | 38.03M | 38.03M |
| Interest Expense | 175K | 176K | 196K | 249K | 249K |
| Other Income / Expenses | 313K | 6.45M | 18.57M | 37.78M | 37.78M |
| Income Before Tax | (100.22M) | (154.81M) | (146.96M) | (223.86M) | (311.62M) |
| Pre-Tax Margin | -137.6% | -330.6% | -187.0% | -475.6% | -795.0% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (100.22M) | (154.81M) | (146.96M) | (223.86M) | (311.4M) |
| Net Margin | -137.6% | -330.6% | -187.0% | -475.6% | -794.4% |
| EPS (Basic) | (2.09) | (2.87) | (2.52) | (2.98) | (3.69) |
| EPS (Diluted) | (2.09) | (2.87) | (2.52) | (2.98) | (3.69) |
| 47.99M | 53.93M | 58.37M | 75.04M | 84.39M | |
| 47.99M | 53.93M | 58.37M | 75.04M | 84.39M |
KYMR Earnings Waterfall · TTM
NASDAQ:KYMR · Revenue to Net Income
Key Ratios
EPS$-3.25
Gross Margin95.7%
Net Margin-1577.9%
P/E Ratio-27.6
P/S Ratio1123.3
Analysis
$105.0M of revenue converted into -$299.6M of net income for the selected period. Gross margin is 95.7% and net margin is -1577.9%, showing how much revenue survives after costs and taxes. EPS is $-3.25, tying the income statement back to per-share earnings.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 8-K | Current report | Oct 29, 2026 | |
| 10-Q | Quarterly report | Oct 29, 2026 | |
| SC 13G/A | SC 13G/A filing | Oct 27, 2026 | |
| 4 | Statement of changes in beneficial ownership | Oct 1, 2026 | |
| SC 13G/A | SC 13G/A filing | Sep 8, 2026 |
How much revenue does KYMR generate?
Kymera Therapeutics, Inc. (KYMR) reported $39.20M of revenue in fiscal 2025.
Is KYMR profitable?
Kymera Therapeutics, Inc. (KYMR) reported -$311.40M of net income, with a net margin of -794.4%.
Continue the stock analysis
Jump to another research area for this company.